IgGenix Demonstrates Potential for an IgG4 Monoclonal Antibody-based Approach to Treating Peanut Allergy

SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–IgGenix, Inc., a preclinical antibody discovery and development company taking a revolutionary approach to directly address allergic disease, today announced advances towards a peanut allergy therapeutic based on IgG4 monoclonal antibodies. These data will be presented during the 2023 European Academy of Allergy and Clinical Immunology…